☆ 4.7 Article

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

BLOOD (2022)

Related references

Note: Only part of the references are listed.

Article Hematology

Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial

Stephane de Botton et al.

Summary: This study compared the efficacy of the oral IDH2 inhibitor enasidenib with conventional care regimens (CCR) in older patients with late-stage mutant-IDH2 AML. Enasidenib significantly improved event-free survival, time to treatment failure, overall response rate, hematologic improvement, and transfusion independence compared to CCR. However, there was no significant difference in overall survival, possibly due to early dropout and subsequent AML-directed therapies.

BLOOD (2023)

Add to Collection

Editorial Material Hematology

Classification of myeloid neoplasms/acute leukemia: Global perspectives and the international consensus classification approach COMMENT

Daniel A. Arber et al.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

Add to Collection

Article Hematology

Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes

Amer M. Zeidan et al.

Summary: Y CC-90002 is an anti-CD47 antibody that inhibits CD47-SIRP alpha interaction and enables macrophage-mediated killing of tumor cells in hematological cancer cell lines. The phase 1 clinical trial in patients with relapsed/refractory AML or high-risk MDS showed that CC-90002 led to mostly adverse events such as diarrhea and thrombocytopenia, with no objective responses observed. Further studies are needed to understand the lack of monotherapy activity and the development of anti-drug antibodies in this treatment.

ANNALS OF HEMATOLOGY (2022)

Add to Collection

Article Hematology

Oral azacitidine prolongs survival of patients with AML in remission independent of measurable residual disease status

Gail J. Roboz et al.

BLOOD (2022)

Add to Collection

Article Hematology

Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial

Alexander E. Perl et al.

Summary: The follow-up of the ADMIRAL trial after 2 years demonstrates that gilteritinib is a safe and effective treatment option for patients with relapsed/refractory FLT3-mutation-positive AML. Gilteritinib therapy provides superior overall survival and long-term remission compared to salvage chemotherapy, especially when used as post-HSCT maintenance.

BLOOD (2022)

Add to Collection

Article Hematology

Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome

Tim Grob et al.

Summary: Mutant TP53 AML and MDS-EB share similar molecular characteristics and survival outcomes, suggesting that they should be considered as distinct molecular disease entities.

BLOOD (2022)

Add to Collection

Article Hematology

Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML

Gabrielle Paras et al.

Summary: In AML, assessing MRD status before and after allogeneic HCT is crucial for predicting patient outcomes. The dynamics of peri-HCT MRD can significantly impact relapse risk and survival probabilities across varying conditioning intensities, improving risk assessment in AML patients compared to isolated pre- or post-HCT MRD assessments.

BLOOD (2022)

Add to Collection

Article Biophysics

Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia

Christoph Schmid et al.

Summary: This study analyzed 318 acute leukemia patients who received DLI after alloSCT, showing that preemptive DLI was effective in reducing MRD and increasing chimerism, thus improving survival rates for patients.

BONE MARROW TRANSPLANTATION (2022)

Add to Collection

Editorial Material Oncology

Time to blur the blast boundaries

Courtney D. DiNardo et al.

Summary: When identifying the optimal therapy for a patient with a myeloid malignancy, focusing on the patient's characteristics and disease cytogenetic and mutational profile is more important than relying solely on the bone marrow blast percentage.

CANCER (2022)

Add to Collection

Article Hematology

Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial

Nigel H. Russell et al.

Summary: Reduced intensity conditioning (RIC) transplantation is a beneficial option for older patients with acute myeloblastic leukemia lacking favorable-risk cytogenetics.

HAEMATOLOGICA (2022)

Add to Collection

Article Oncology

Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation

Christopher J. Gibson et al.

Summary: Donor clonal hematopoiesis (CH) has a significant impact on clinical outcomes and graft alloimmune function in transplant recipients. DNMT3A-CH is associated with improved recipient survival and an augmented network of inflammatory cytokines in recipients. Different mutations may contribute to donor cell leukemia (DCL) in allogeneic hematopoietic cell transplantation.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses

Kelly J. Norsworthy et al.

Summary: The study explores the associations between response and survival outcomes in newly diagnosed acute myeloid leukemia (AML) patients undergoing intensive chemotherapy. The analysis reveals a moderate association between complete remission (CR) rate and overall survival (OS), and a strong association between event-free survival (EFS) and OS. However, the confidence intervals are wide, and the results became moderate when using alternative definitions for EFS. Patient-level analysis shows that CR responders have better OS compared to CRi or CRp responders and nonresponders.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Hematology

TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML

Olga K. Weinberg et al.

Summary: This study evaluated the clinicopathologic features and outcomes of AML and MDS patients with complex karyotype (CK). The presence of TP53 mutation, especially multihit TP53 mutation, in the context of CK, identified a homogeneously aggressive disease, irrespective of blast count or therapy-relatedness.

BLOOD ADVANCES (2022)

Add to Collection

Article Hematology

Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal

Elihu Estey et al.

Summary: Including patients with 10% to 30% blasts (AML/MDS) in both AML and MDS studies would allow for testing the independent effect of blast percentage on outcome, provide more treatment options for patients, and potentially simplify the regulatory approval process.

BLOOD (2022)

Add to Collection

Article Hematology

Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML

Fei Yang et al.

Summary: Inherited predisposition to myeloid malignancies is more common than previously appreciated. Through whole-exome sequencing analysis on 391 adult patients, it was found that pathogenic/likely pathogenic germline variants were identified in 13.6% of acute myeloid leukemia (AML) patients in 34 genes. This highlights the need for a comprehensive understanding of the predisposition potential of many germline variants.

BLOOD (2022)

Add to Collection

Article Hematology

One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors

Dietger Niederwieser et al.

Summary: The Worldwide Network of Blood and Marrow Transplantation promotes hematopoietic cell transplantation by evaluating activities through member societies, national registries, and individual centers. The number of HCT procedures is increasing globally, with narrowing gaps between regions.

HAEMATOLOGICA (2022)

Add to Collection

Article Oncology

FDA Approval Summary: Oral Azacitidine for Continued Treatment of Adults with Acute Myeloid Leukemia Unable to Complete Intensive Curative Therapy

Emily Y. Jen et al.

Summary: On September 1, 2020, the FDA approved the oral medication plete remission (CR) for the treatment of AML patients who are unable to undergo intensive curative therapy. The approval was based on a randomized trial (CC-486-AML-001) which showed improved overall survival in adults aged 55 years and above with AML in CR/CRi who received daily doses of 300 mg CC-486 on a 2 weeks on/2 weeks off schedule.

CLINICAL CANCER RESEARCH (2022)

Add to Collection

Article Oncology

Measurable Residual Disease Response and Prognosis in Treatment-Naive Acute Myeloid Leukemia With Venetoclax and Azacitidine

Keith W. Pratz et al.

Summary: This study explored the outcomes of patients with acute myeloid leukemia treated with venetoclax and azacitidine who achieved composite complete remission (CRc) and measurable residual disease (MRD) < 10(-3). The results showed that patients who achieved CRc and MRD < 10(-3) had longer duration of remission, event-free survival, and overall survival compared to those with MRD >= 10(-3).

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration

Luca Vincenzo Cappelli et al.

Summary: In AML patients, persistence or acquisition of non-DTA mutations during complete molecular remission is associated with worse prognosis, while the inclusion of predictive mutations with DTA genes defines a new group. CHOP-like mutations are significantly linked to inferior outcomes and their detection at relapse is detrimental.

LEUKEMIA (2022)

Add to Collection

Article Medicine, General & Internal

Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia

Pau Montesinos et al.

Summary: This study demonstrated that the combination therapy of oral ivosidenib and azacitidine showed better event-free survival and longer overall survival in patients with newly diagnosed IDH1-mutated acute myeloid leukemia.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Hematology

Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia

Satoshi Wakita et al.

Summary: Mutations of CCAAT/enhancer-binding protein alpha (CEBPAmu) significantly impact the prognosis of acute myeloid leukemia (AML). Particularly, CEBPAmu in the basic leucine zipper domain (bZIP) is strongly associated with a favorable prognosis and can serve as a potent marker for AML prognosis. This finding has implications for treatment stratification and the development of targeted therapeutic approaches in CEBPA-mutated AML.

BLOOD ADVANCES (2022)

Add to Collection

Article Hematology

Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications

Hartmut Doehner et al.

Summary: This study evaluated the efficacy of midostaurin in combination with intensive chemotherapy, followed by allogeneic hematopoietic-cell transplantation (HCT) and a 1-year midostaurin maintenance therapy, in adult patients with acute myeloid leukemia (AML) and fms-related tyrosine kinase 3 (FLT3) internal tandem duplication (ITD). The results showed that adding midostaurin to intensive therapy significantly improved the outcome in both younger and older AML patients with FLT3-ITD.

BLOOD ADVANCES (2022)

Add to Collection

Article Hematology

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Daniel A. Arber et al.

Summary: In 2016, the WHO, Society for Hematopathology, and European Association for Haematopathology collaborated to update the classification of myeloid neoplasms and acute leukemias, advancing the field of myeloid neoplasms and acute leukemias.

BLOOD (2022)

Add to Collection

Letter Hematology

Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating agent and venetoclax regimens

Abhishek Maiti et al.

HAEMATOLOGICA (2021)

Add to Collection

Review Hematology

Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy

Bhagirathbhai Dholaria et al.

Summary: This evidence-based review examines the role of hematopoietic cell transplantation (HCT) in the management of newly diagnosed adult acute myeloid leukemia (AML) and recommends the preferential use of allogeneic HCT with myeloablative conditioning in eligible patients. Allogeneic HCT offers a survival benefit in intermediate- and high-risk AML patients and is now considered part of standard clinical care.

TRANSPLANTATION AND CELLULAR THERAPY (2021)

Add to Collection

Article Hematology

Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

Geoffrey L. Uy et al.

Summary: This study presents the results of a multicenter, open-label, phase 1/2 study of flotetuzumab in 88 adults with relapsed/refractory AML, showing clinical benefits in PIF/ER patients and encouraging evidence of activity. Flotetuzumab represents an innovative experimental approach associated with acceptable safety.

BLOOD (2021)

Add to Collection

Review Hematology

How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML)

Richard Dillon et al.

Summary: Recent years have seen significant advances in the use of molecular diagnostic and monitoring techniques for patients with acute myeloid leukaemia (AML), coupled with the development of new therapeutic agents. This has led to potential improvements in treatment algorithms. The article highlights the importance of molecular monitoring in refining clinical decision-making and personalizing treatment for AML patients, with practical recommendations provided for cases where evidence is lacking or conflicting. Additionally, important technical considerations for clinicians to safely utilize these technologies are reviewed as they become more widely implemented.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

Add to Collection

Article Biophysics

ELN risk stratification and outcomes in secondary and therapy-related AML patients consolidated with allogeneic stem cell transplantation

Madlen Jentzsch et al.

Summary: Secondary or therapy-related acute myeloid leukemia (s/tAML) patients have inferior outcomes after chemotherapy and often receive allogeneic stem cell transplantation for consolidation. In the ELN favorable risk group, s/tAML patients have a higher cumulative incidence of relapse compared to de novo AML patients. However, outcomes are similar between de novo and s/tAML patients in the ELN intermediate and adverse risk group.

BONE MARROW TRANSPLANTATION (2021)

Add to Collection

Review Hematology

Inherited predisposition to haematopoietic malignancies: overcoming barriers and exploring opportunities

Amy M. Trottier et al.

Summary: Inherited predisposition to haematopoietic malignancies can lead to common misconceptions, including the rarity of inherited haematological malignancy syndromes, the mutual exclusivity between myeloid and lymphoid malignancy predisposition syndromes, and the uniqueness and distinctness of solid tumor predisposition syndromes from haematopoietic malignancy predisposition syndromes.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

Add to Collection

Article Hematology

Effectiveness of allogeneic hematopoietic cell transplantation for older patients with acute myeloid leukemia

Frederick R. Appelbaum

Summary: Conventional chemotherapy for older AML patients has poor outcomes and few cures. Allogeneic hematopoietic cell transplantation offers the best chance for cure in younger patients, but is rarely used for older patients, despite recent improvements in safety. This report will address the frequency of transplantation for AML by age, the impact of age on transplant outcomes, comparative outcomes of transplantation versus chemotherapy for older AML patients, and methods to improve allogeneic HCT outcomes in older AML patients.

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2021)

Add to Collection

Article Hematology

Since everyone has a donor, why are some eligible patients still not transplanted?

Mary Eapen

Summary: Hematopoietic cell transplantation is a significant treatment option for blood diseases, but many patients may be unable to access it due to factors such as age, health conditions, ethnicity, and financial status, among others. New pharmacologic and cellular therapies offer potential alternatives for those who are not suitable for transplantation.

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2021)

Add to Collection

Editorial Material Hematology

CEBPA bZip mutations: just a single shot

Jorge Sierra et al.

Summary: In this study, Tarlock and colleagues showed that biallelic and single bZIP CEBPA mutations have similarly favorable prognostic impact in AML in a large cohort of children, adolescents, and young adults.

BLOOD (2021)

Add to Collection

Article Hematology

2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

Michael Heuser et al.

Summary: The European LeukemiaNet MRD Working Party updated the 2018 MRD recommendations, including technical specifications and integrative assessments. They also proposed the use of MRD as a prognostic and surrogate endpoint for drug testing, as well as the clinical implications of MRD assessment in AML. Recommendations include technical requirements for flow cytometry and molecular MRD analysis, as well as reporting methods for MRD results.

BLOOD (2021)

Add to Collection

Article Oncology

Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia

Charles Craddock et al.

Summary: The intensified RIC conditioning regimen, FLAMSA-Bu, did not improve outcomes for adults undergoing transplantation for high-risk AML or MDS, regardless of pretransplant MRD status. Pretransplant detectable MRD was associated with disease relapse, but acquisition of full donor T-cell chimerism improved overall survival.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Acute Myeloid Leukemia, Version 2.2021 Featured Updates to the NCCN Guidelines

Daniel A. Pollyea et al.

Summary: The NCCN Guidelines for Acute Myeloid Leukemia provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment. Recent updates focus on familial genetic alterations, treatment strategies for low-risk and favorable-risk AML, venetoclax-based therapies, and considerations for patients who prefer not to receive blood transfusions.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)

Add to Collection

Article Oncology

Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemia

Xueyan Chen et al.

Summary: sAML and MDS-EB share many similarities, including similar mutation distribution and treatment response. This suggests that they may represent different stages or lineages of the same disease.

LEUKEMIA & LYMPHOMA (2021)

Add to Collection

Article Hematology

Genomic characteristics and prognostic significance of co-mutated ASXL1/SRSF2 acute myeloid leukemia

Daniel R. Richardson et al.

Summary: The ASXL1 and SRSF2 mutations in AML are frequently associated with poor outcomes, especially in patients with preexisting myeloid malignancies. Patients with co-mutations of ASXL1 and SRSF2 have a higher probability of death compared to those with single mutations, with a trend towards inferior overall survival, largely attributable to a high proportion of secondary-AML patients in this cohort.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

Add to Collection

Letter Hematology

Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML

Martin Wermke et al.

BLOOD (2021)

Add to Collection

Article Hematology

Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin

Laura K. Schmalbrock et al.

Summary: This study investigated clonal evolution and resistance mechanisms in FLT3-ITD-mutated AML patients treated with midostaurin, revealing that some patients acquired mutations in signaling pathways, such as MAPK, after becoming FLT3-ITD negative, while others showed no FLT3-ITD mutational changes, suggesting alternative resistance mechanisms or loss of midostaurin inhibitory activity due to inadequate drug levels.

BLOOD (2021)

Add to Collection

Article Hematology

Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study

Sabine Kayser et al.

Summary: Patients with t(8;16) AML have poor outcomes with chemotherapy, but may see substantial improvement with allogeneic hematopoietic cell transplantation performed in first complete remission (CR1).

BRITISH JOURNAL OF HAEMATOLOGY (2021)

Add to Collection

Article Oncology

Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial

Richard A. Larson et al.

Summary: The addition of midostaurin to standard chemotherapy in FLT3-mutant AML patients has shown significant benefits in reducing the risk of death and relapse. However, the impact of maintenance therapy on overall outcomes remains inconclusive.

LEUKEMIA (2021)

Add to Collection

Article Pathology

Myelodysplastic syndrome with t(6;9)(p22;q34.1)/DEK-NUP214 better classified as acute myeloid leukemia? A multicenter study of 107 cases

Hong Fang et al.

Summary: The t(6;9)(p22;q34.1)/DEK-NUP214 is a recurrent genetic abnormality seen in 1-2% of AML patients, and rarely in MDS. This study compared 107 patients with t(6;9)/DEK-NUP214 myeloid neoplasms, revealing older age, lower white blood cell count, lower blast count, higher platelet count, and lower FLT3-ITD mutation frequency in MDS patients compared to AML patients. Survival was not significantly different between MDS and AML patients, but MDS patients showed a trend towards better survival. Multivariate analysis indicated that initial diagnosis and stem cell transplantation were prognostic factors for survival. Stem cell transplantation greatly improved survival in patients with t(6;9)/DEK-NUP214 myeloid neoplasms.

MODERN PATHOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

The acquisition of molecular drivers in pediatric therapy-related myeloid neoplasms

Jason R. Schwartz et al.

Summary: Pediatric therapy-related myeloid neoplasms have specific somatic drivers at the genomic level, unlike adults, with no evidence of pre-existing minor tMN clones associated with TP53 mutations.

NATURE COMMUNICATIONS (2021)

Add to Collection

Review Oncology

Clinical Implications of Inflammation in Acute Myeloid Leukemia

Christian Recher

Summary: Recent advances in understanding the tumor microenvironment of acute myeloid leukemia suggest that inflammation may play a significant role in aspects such as disease progression, chemoresistance, and myelosuppression. Mutated oncogenes like RUNX1, NPM1, and SRSF2 may modulate cell sensitivity to glucocorticoids. In clinical practice, inflammatory markers like serum ferritin or IL-6 have a strong prognostic impact on disease progression and outcomes.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Hematology

CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group

Katherine Tarlock et al.

Summary: Biallelic CEBPA mutations, especially CEBPA-bZip mutations, are associated with favorable clinical outcomes in AML patients. The presence of a second CEBPA mutation does not significantly affect survival rates. Co-occurring mutations in CSF3R and GATA2 can impact the overall prognosis in CEBPA-mutated patients.

BLOOD (2021)

Add to Collection

Review Hematology

What's new in the pathogenesis and treatment of therapy-related myeloid neoplasms

Maria Teresa Voso et al.

Summary: Therapy-related myeloid neoplasms (t-MNs) are diseases occurring in patients treated with chemo- and/or radiotherapy for a primary cancer or an autoimmune disorder, with genetic factors and previous disease history playing significant roles. Treatment options for t-MNs include new drugs and allogeneic stem cell transplantation as the best therapeutic choice for fit patients with unfavorable genetic profiles.

BLOOD (2021)

Add to Collection

Article Hematology

HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis

Mahasweta Gooptu et al.

Summary: After comparing outcomes of 2036 haploidentical and 284 matched unrelated donor (MUD) transplantations with posttransplant cyclophosphamide (PTCy) graft-versus-host disease (GVHD) prophylaxis, it was found that MUD transplants had lower acute GVHD and nonrelapse mortality rates, as well as higher disease-free and overall survival, especially in recipients of reduced-intensity regimens. However, no significant differences were observed in patients receiving myeloablative conditioning regimens, highlighting the importance of donor-recipient HLA matching for allogeneic transplantation.

BLOOD (2021)

Add to Collection

Review Hematology

Management of Disseminated Intravascular Coagulation in Acute Leukemias

Hugo ten Cate et al.

Summary: DIC is a vascular disorder characterized by coagulation activation, diagnosed with hemostatic abnormalities. It is common in acute leukemia patients, with varying clinical consequences and management approaches based on leukemia subtype. Management focuses on treating the underlying disease and minimizing bleeding risk, with liberal use of blood products in hemorrhagic phenotypes.

HAMOSTASEOLOGIE (2021)

Add to Collection

Review Oncology

Molecular Minimal Residual Disease Detection in Acute Myeloid Leukemia

Christian M. Vonk et al.

Summary: Although most AML patients achieve CR after initial induction chemotherapy, residual leukemic cells may lead to relapse, with MRD serving as a prognostic marker. Molecular techniques like NGS offer a sensitive assessment of MRD markers, but face challenges such as limited sensitivity/specificity and difficulty in distinguishing mutations. Multiple studies have explored the association between MRD detection by molecular assays and AML relapse, highlighting limitations, challenges, and opportunities.

CANCERS (2021)

Add to Collection

Review Oncology

Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations

Roland B. Walter et al.

Summary: MRD testing in AML is an important biomarker for predicting patient outcomes and early detection of relapse. However, there are still open questions regarding the optimal timing and frequency of testing, as well as defining thresholds for relapse. Studies confirming the direct impact of treatment effects on MRD to clinical outcomes are needed to establish MRD as a surrogate endpoint in AML.

LEUKEMIA (2021)

Add to Collection

Article Hematology

Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia

Ing S. Tiong et al.

Summary: Monitoring of NPM1 mutant measurable residual disease in AML patients treated with intensive chemotherapy is crucial. Persistence of low copy number MRD post-treatment is associated with disease progression, with preemptive salvage therapy showing significant benefits. Risk factors for disease progression include FLT3-internal tandem duplication at diagnosis and suboptimal MRD response at EOT.

BLOOD ADVANCES (2021)

Add to Collection

Review Oncology

Towards precision medicine for AML

Hartmut Dohner et al.

Summary: The rapid advances in sequencing technologies have greatly improved our understanding of AML at the molecular level, leading to the development of precision medicine approaches. Challenges in this field include safely combining agents with different mechanisms of action, overcoming primary and secondary resistance, and designing future clinical trials to address these issues.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

Add to Collection

Review Immunology

Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Who, When, and How?

Justin Loke et al.

Summary: While most AML patients achieve complete remission with intensive chemotherapy, many face a risk of relapse if treated with chemotherapy alone. Allogeneic stem cell transplant has become a key treatment strategy for AML patients, especially for those in first complete remission and advanced stages. Despite a decrease in transplant-related mortality, there remains a need to address the risk of disease relapse.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Hematology

Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia

Abhishek Maiti et al.

Summary: Assessment of measurable residual disease (MRD) provides prognostic information in acute myeloid leukemia (AML). However, it remains unclear how MRD status impacts survival outcomes in older/unfit patients receiving first-line therapy with 10-day decitabine and venetoclax. This study found that achieving a negative MRD at 1, 2, and 4 months post-treatment significantly improved survival in this patient population.

BLOOD ADVANCES (2021)

Add to Collection

Article Hematology

Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations

Michael Heuser et al.

Summary: Non-DTA mutations serve as prognostic NGS-MRD markers post-alloHCT in patients with acute myeloid leukemia, while MRD positivity is an independent adverse predictor of relapse, relapse-free survival, and overall survival.

BLOOD ADVANCES (2021)

Add to Collection

Article Hematology

Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials

Thomas Heinicke et al.

Summary: Relapse of acute leukemia is a common complication with uncertain outcomes, affecting both younger and older patients. Factors such as hematopoietic cell transplantation and long-term remission are beneficial, while challenges remain in the treatment and prognosis of relapse.

ANNALS OF HEMATOLOGY (2021)

Add to Collection

Article Hematology

Machine Learning Integrates Genomic Signatures for Subclassification Beyond Primary and Secondary Acute Myeloid Leukemia

Hassan Awada et al.

BLOOD (2021)

Add to Collection

Article Hematology

CEBPA Mutations in 4708 Patients with Acute Myeloid Leukemia - Differential Impact of bZIP and TAD Mutations on Outcome

Franziska Taube et al.

BLOOD (2021)

Add to Collection

Article Hematology

CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial

Jeffrey E Lancet et al.

Lancet Haematology (2021)

Add to Collection

Article Hematology

Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification

Inge van der Werf et al.

Summary: Splicing factor (SF) mutations in patients with acute myeloid leukemia (AML) are associated with unfavorable clinical features, adverse risk factors, and shorter survival. SF3B1 mutations indicate relatively poor prognosis, especially in certain risk groups. The prognostic value of RUNX1 mutations seems to be limited to its co-occurrence with SF mutations.

BLOOD ADVANCES (2021)

Add to Collection

Meeting Abstract Hematology

Safety and Efficacy of Menin Inhibition in Patients (Pts) with MLL-Rearranged and NPM1 Mutant Acute Leukemia: A Phase (Ph) 1, First-in-Human Study of SNDX-5613 (AUGMENT 101)

Eytan M. Stein et al.

BLOOD (2021)

Add to Collection

Review Oncology

Inherited Susceptibility to Hematopoietic Malignancies in the Era of Precision Oncology

Gregory W. Roloff et al.

Summary: This article discusses strategies for identifying patients with hereditary hematopoietic malignancies, molecular testing, and clinical surveillance recommendations. It also highlights the risks and prognosis associated with HHMs, as well as considerations for allogeneic stem cell transplantation and contemporary issues in precision oncology.

JCO PRECISION ONCOLOGY (2021)

Add to Collection

Article Hematology

Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial

Bart L. Scott et al.

Summary: This study provides long-term follow-up results of a randomized comparison of myeloablative conditioning (MAC) and reduced-intensity conditioning (MC) before allogeneic hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML) or myelodysplasia (MDS). The findings suggest that while MAC patients had higher transplant-related mortality (TRM), they had significantly better overall survival compared to RIC patients. The study highlights the importance of conditioning intensity in determining outcomes post-HCT for AML and MDS patients.

TRANSPLANTATION AND CELLULAR THERAPY (2021)

Add to Collection

Article Hematology

How I treat acute myeloid leukemia in the era of new drugs

Courtney D. DiNardo et al.

BLOOD (2020)

Add to Collection

Article Pathology

Genetic Factors in Acute Myeloid Leukemia With Myelodysplasia-Related Changes A Study of 186 Cases

Hong Fang et al.

AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2020)

Add to Collection

Article Hematology

Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy

Guillermo Montalban-Bravo et al.

AMERICAN JOURNAL OF HEMATOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003-2007 Versus 2013-2017 Cohorts

George B. McDonald et al.

ANNALS OF INTERNAL MEDICINE (2020)

Add to Collection

Article Hematology

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

C. D. DiNardo et al.

BLOOD (2020)

Add to Collection

Article Hematology

Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia

Konstanze Doehner et al.

BLOOD (2020)

Add to Collection

Article Hematology

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia

Gail J. Roboz et al.

BLOOD (2020)

Add to Collection

Review Hematology

Next-generation sequencing for measurable residual disease detection in acute myeloid leukaemia

Jack Ghannam et al.

BRITISH JOURNAL OF HAEMATOLOGY (2020)

Add to Collection

Review Hematology

The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience

Justin Loke et al.

BRITISH JOURNAL OF HAEMATOLOGY (2020)

Add to Collection

Article Oncology

Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease

Christopher S. Hourigan et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study

Richard F. Schlenk et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study

Maximilian Stahl et al.

LEUKEMIA (2020)

Add to Collection

Review Oncology

Is There Still a Role for Autologous Stem Cell Transplantation for the Treatment of Acute Myeloid Leukemia?

Felicetto Ferrara et al.

CANCERS (2020)

Add to Collection

Review Hematology

Current Use of and Trends in Hematopoietic Cell Transplantation in the United States

Anita D'Souza et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)

Add to Collection

Article Hematology

Atypical 3q26/MECOM rearrangements genocopy inv(3)/t(3;3) in acute myeloid leukemia

Sophie Ottema et al.

BLOOD (2020)

Add to Collection

Article Hematology

Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study

Guillermo Garcia-Manero et al.

BLOOD (2020)

Add to Collection

Article Hematology

Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia

Robert P. Hasserjian et al.

BLOOD (2020)

Add to Collection

Article Hematology

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

Andrew H. Wei et al.

BLOOD (2020)

Add to Collection

Article Hematology

Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?

Christoph Roellig et al.

BLOOD (2020)

Add to Collection

Article Oncology

Pathogenic Germline Mutations in DNA Repair Genes in Combination With Cancer Treatment Exposures and Risk of Subsequent Neoplasms Among Long-Term Survivors of Childhood Cancer

Na Qin et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN)

Andreas Burchert et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Hematology

Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results

Claude Gardin et al.

BLOOD ADVANCES (2020)

Add to Collection

Article Hematology

Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcome

Pierre-Yves Dumas et al.

BLOOD ADVANCES (2020)

Add to Collection

Article Oncology

Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial

Li Xuan et al.

LANCET ONCOLOGY (2020)

Add to Collection

Article Hematology

Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial

Silke Kapp-Schwoerer et al.

BLOOD (2020)

Add to Collection

Article Medicine, General & Internal

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

C. D. DiNardo et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Review Hematology

Leukapheresis for the management of hyperleukocytosis in acute myeloid leukemia-A systematic review and meta-analysis

Jan P. Bewersdorf et al.

TRANSFUSION (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial

Amy Burd et al.

NATURE MEDICINE (2020)

Add to Collection

Review Oncology

Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia A Systematic Review and Meta-analysis

Nicholas J. Short et al.

JAMA ONCOLOGY (2020)

Add to Collection

Review Cell Biology

Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments?

Jan Philipp Bewersdorf et al.

CELLS (2020)

Add to Collection

Review Biochemistry & Molecular Biology

NPM1-Mutated Myeloid Neoplasms with <20% Blasts: A Really Distinct Clinico-Pathologic Entity?

Fabio Forghieri et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

Add to Collection

Article Medicine, General & Internal

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission

A. H. Wei et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Hematology

Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia

Nicholas J. Short et al.

BLOOD ADVANCES (2020)

Add to Collection

Article Hematology

High progression-free survival after intermediate intensity double unit cord blood transplantation in adults

Juliet N. Barker et al.

BLOOD ADVANCES (2020)

Add to Collection

Article Hematology

A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients

Betul Oran et al.

BLOOD ADVANCES (2020)

Add to Collection

Article Hematology

Clonal hematopoiesis predicts development of therapy-related myeloid neoplasms post-autologous stem cell transplantation

Johannes Frasez Soerensen et al.

BLOOD ADVANCES (2020)

Add to Collection

Article Hematology

Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial

Juliette Lambert et al.

HAEMATOLOGICA (2019)

Add to Collection

Article Hematology

Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet

Miguel A. Sanz et al.

BLOOD (2019)

Add to Collection

Article Hematology

Hereditary myeloid malignancies

Hind Rafei et al.

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2019)

Add to Collection

Article Oncology

Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study

Celalettin Ustun et al.

LEUKEMIA (2019)

Add to Collection

Article Oncology

Variant allele frequencies do not correlate well with myeloblast counts in a clinically validated gene sequencing panel for routine acute myeloid leukemia workup

Laura N. Toth et al.

LEUKEMIA & LYMPHOMA (2019)

Add to Collection

Article Oncology

Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia

Christine M. McMahon et al.

CANCER DISCOVERY (2019)

Add to Collection

Review Pathology

Germline Predisposition to Hematolymphoid Neoplasia 2017 Society for Hematopathology/European Association for Haematopathology Workshop Report

Olga K. Weinberg et al.

AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2019)

Add to Collection

Article Hematology

Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age >69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Olle Ringden et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)

Add to Collection

Article Hematology

Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR

Jason Dehn et al.

BLOOD (2019)

Add to Collection

Article Hematology

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue

Anand Padmanabhan et al.

JOURNAL OF CLINICAL APHERESIS (2019)

Add to Collection

Article Oncology

Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial

Jorge E. Cortes et al.

LANCET ONCOLOGY (2019)

Add to Collection

Article Hematology

GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia

Adriano Venditti et al.

BLOOD (2019)

Add to Collection

Article Hematology

Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group

Frank G. Ruecker et al.

BLOOD (2019)

Add to Collection

Article Oncology

Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts

Linus Angenendt et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Review Multidisciplinary Sciences

Clonal hematopoiesis in human aging and disease

Siddhartha Jaiswal et al.

SCIENCE (2019)

Add to Collection

Article Hematology

Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib

Eytan M. Stein et al.

BLOOD (2019)

Add to Collection

Article Hematology

Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients

Gerwin Huls et al.

BLOOD (2019)

Add to Collection

Article Hematology

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

Courtney D. DiNardo et al.

BLOOD (2019)

Add to Collection

Article Oncology

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

Jorge E. Cortes et al.

LEUKEMIA (2019)

Add to Collection

Article Oncology

CD34+CD38- leukemic stem cell frequency to predict outcome in acute myeloid leukemia

Wendelien Zeijlemaker et al.

LEUKEMIA (2019)

Add to Collection

Article Oncology

Association of Chemotherapy for Solid Tumors With Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern Era

Lindsay M. Morton et al.

JAMA ONCOLOGY (2019)

Add to Collection

Article Hematology

Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms

Sanjay S. Patel et al.

BLOOD ADVANCES (2019)

Add to Collection

Article Hematology

NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy

Guillermo Montalban-Bravo et al.

BLOOD ADVANCES (2019)

Add to Collection

Article Hematology

Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience

Chezi Ganzel et al.

AMERICAN JOURNAL OF HEMATOLOGY (2018)

Add to Collection

Article Hematology

Association of mutations with morphological dysplasia in de novo acute myeloid leukemia without 2016 WHO Classification-defined cytogenetic abnormalities

Olga K. Weinberg et al.

HAEMATOLOGICA (2018)

Add to Collection

Article Oncology

Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations

Sylvie D. Freeman et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Article Oncology

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia

Jeffrey E. Lancet et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML

C. D. DiNardo et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Medicine, General & Internal

Molecular Minimal Residual Disease in Acute Myeloid Leukemia

M. Jongen-Lavrencic et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Hematology

Association of mutations with morphological dysplasia in de novo acute myeloid leukemia without 2016 WHO Classification-defined cytogenetic abnormalities

Olga K. Weinberg et al.

HAEMATOLOGICA (2018)

Add to Collection

Article Oncology

Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2 Analysis of a Phase 1/2 Study

Amir T. Fathi et al.

JAMA ONCOLOGY (2018)

Add to Collection

Article Oncology

Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse

Mohamed A. Kharfan-Dabaja et al.

JAMA ONCOLOGY (2018)

Add to Collection

Article Multidisciplinary Sciences

Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations

Andrew M. Intlekofer et al.

NATURE (2018)

Add to Collection

Review Hematology

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

Hartmut Doehner et al.

BLOOD (2017)

Add to Collection

Article Hematology

Leukemic stem cells: identification and clinical application

Diana Hanekamp et al.

INTERNATIONAL JOURNAL OF HEMATOLOGY (2017)

Add to Collection

Article Oncology

Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group

Marie Balsat et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection

Article Oncology

Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes

Bart L. Scott et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection

Article Medicine, General & Internal

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

R. M. Stone et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Oncology

Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia

S. Jaramillo et al.

BLOOD CANCER JOURNAL (2017)

Add to Collection

Review Hematology

Prognostic Scoring Systems in Allogeneic Hematopoietic Stem Cell Transplantation: Where Do We Stand?

Rashmika Potdar et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)

Add to Collection

Article Cell & Tissue Engineering

Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes

Catherine C. Coombs et al.

CELL STEM CELL (2017)

Add to Collection

Review Oncology

Therapy-related myeloid neoplasms: when genetics and environment collide

Megan E. McNerney et al.

NATURE REVIEWS CANCER (2017)

Add to Collection

Article Hematology

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Eytan M. Stein et al.

BLOOD (2017)

Add to Collection

Letter Hematology

More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia

Guillermo Montalban-Bravo et al.

BLOOD (2017)

Add to Collection

Article Pharmacology & Pharmacy

Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments

Suresh K. Agarwal et al.

CLINICAL THERAPEUTICS (2017)

Add to Collection

Review Hematology

Hematopoietic stem cell transplantation for patients with AML in first complete remission

Jan J. Cornelissen et al.

BLOOD (2016)

Add to Collection

Article Oncology

Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia

Jane E. Churpek et al.

CANCER (2016)

Add to Collection

Article Hematology

Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial

Christophe Willekens et al.

HAEMATOLOGICA (2016)

Add to Collection

Article Hematology

Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial

Christophe Willekens et al.

HAEMATOLOGICA (2016)

Add to Collection

Article Hematology

Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)

Courtney D. DiNardo et al.

AMERICAN JOURNAL OF HEMATOLOGY (2016)

Add to Collection

Article Hematology

Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016

Andrew J. Ullmann et al.

ANNALS OF HEMATOLOGY (2016)

Add to Collection

Review Hematology

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

Daniel A. Arber et al.

BLOOD (2016)

Add to Collection

Article Hematology

TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation

Jan M. Middeke et al.

BRITISH JOURNAL OF HAEMATOLOGY (2016)

Add to Collection

Article Hematology

Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia

Charles Craddock et al.

HAEMATOLOGICA (2016)

Add to Collection

Article Hematology

An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation

Paul Ferguson et al.

HAEMATOLOGICA (2016)

Add to Collection

Article Oncology

PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations

Paul D. P. Pharoah et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)

Add to Collection

Article Medicine, General & Internal

Cord-Blood Transplantation in Patients with Minimal Residual Disease

Filippo Milano et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Medicine, General & Internal

Assessment of Minimal Residual Disease in Standard-Risk AML

A. Ivey et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Medicine, General & Internal

Genomic Classification and Prognosis in Acute Myeloid Leukemia

Elli Papaemmanuil et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Hematology

Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia

Charles Craddock et al.

HAEMATOLOGICA (2016)

Add to Collection

Article Hematology

An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation

Paul Ferguson et al.

HAEMATOLOGICA (2016)

Add to Collection

Article Oncology

PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations

Paul D. P. Pharoah et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)

Add to Collection

Article Oncology

Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma

Elizabeth M. Swisher et al.

JAMA ONCOLOGY (2016)

Add to Collection

Review Hematology

Monitoring minimal residual disease in acute myeloid leukaemia: a review of the current evolving strategies

Hans Beier Ommen

THERAPEUTIC ADVANCES IN HEMATOLOGY (2016)

Add to Collection

Review Pathology

Acute Myeloid Leukemia With Recurrent Cytogenetic Abnormalities

Kathryn Foucar et al.

AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2015)

Add to Collection

Article Hematology

Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation

Natasha Kekre et al.

HAEMATOLOGICA (2015)

Add to Collection

Article Oncology

Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults

Yvette L. Kasamon et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

Add to Collection

Article Oncology

Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases

Chi Young Ok et al.

LEUKEMIA RESEARCH (2015)

Add to Collection

Article Hematology

Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation

Natasha Kekre et al.

HAEMATOLOGICA (2015)

Add to Collection

Article Hematology

Acute myeloid leukemia ontogeny is defined by distinct somatic mutations

R. Coleman Lindsley et al.

BLOOD (2015)

Add to Collection

Article Oncology

Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation

R. B. Walter et al.

LEUKEMIA (2015)

Add to Collection

Article Multidisciplinary Sciences

Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia

Terrence N. Wong et al.

NATURE (2015)

Add to Collection

Review Biophysics

Application of machine learning algorithms for clinical predictive modeling: a data-mining approach in SCT

R. Shouval et al.

BONE MARROW TRANSPLANTATION (2014)

Add to Collection

Article Hematology

Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study

Heesun J. Rogers et al.

HAEMATOLOGICA (2014)

Add to Collection

Article Oncology

Comorbidity-Age Index: A Clinical Measure of Biologic Age Before Allogeneic Hematopoietic Cell Transplantation

Mohamed L. Sorror et al.

JOURNAL OF CLINICAL ONCOLOGY (2014)

Add to Collection

Article Oncology

Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials

Robert K. Hills et al.

LANCET ONCOLOGY (2014)

Add to Collection

Letter Oncology

Application of the International Prognostic Scoring System-Revised in therapy-related myelodysplastic syndromes and oligoblastic acute myeloid leukemia

C. Y. Ok et al.

LEUKEMIA (2014)

Add to Collection

Article Oncology

Hyperdiploidy with 49-65 chromosomes represents a heterogeneous cytogenetic subgroup of acute myeloid leukemia with differential outcome

L. Chilton et al.

LEUKEMIA (2014)

Add to Collection

Article Hematology

Sense and nonsense of high-dose cytarabine for acute myeloid leukemia

Bob Lowenberg

BLOOD (2013)

Add to Collection

Article Medical Laboratory Technology

Validation of Cell-based Fluorescence Assays: Practice Guidelines from the ICSH and ICCS - Part V - Assay Performance Criteria

Brent Wood et al.

CYTOMETRY PART B-CLINICAL CYTOMETRY (2013)

Add to Collection

Article Oncology

High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study

Monique Terwijn et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

Add to Collection

Article Oncology

Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial

Alan K. Burnett et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

Add to Collection

Article Medicine, General & Internal

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

Timothy J. Ley et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Add to Collection

Review Immunology

European guidelines for prevention and management of influenza in hematopoietic stem cell transplantation and leukemia patients: summary of ECIL-4 (2011), on behalf of ECIL, a joint venture of EBMT, EORTC, ICHS, and ELN

D. Engelhard et al.

TRANSPLANT INFECTIOUS DISEASE (2013)

Add to Collection

Article Hematology

TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome

Frank G. Rueckner et al.

BLOOD (2012)

Add to Collection

Article Hematology

A disease risk index for patients undergoing allogeneic stem cell transplantation

Philippe Armand et al.

BLOOD (2012)

Add to Collection

Article Hematology

PRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies

Francois P. Duhoux et al.

BRITISH JOURNAL OF HAEMATOLOGY (2012)

Add to Collection

Article Oncology

Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia

Alan K. Burnett et al.

JOURNAL OF CLINICAL ONCOLOGY (2012)

Add to Collection

Article Genetics & Heredity

Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms

Eduard Schulz et al.

JOURNAL OF MEDICAL GENETICS (2012)

Add to Collection

Article Medicine, General & Internal

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

Sylvie Castaigne et al.

LANCET (2012)

Add to Collection

Article Pathology

Myelodysplastic Syndrome With inv(3)(q21q26.2) or t(3;3)(q21;q26.2) Has a High Risk for Progression to Acute Myeloid Leukemia

Wei Cui et al.

AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2011)

Add to Collection

Article Hematology

The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML

Sabine Kayser et al.

BLOOD (2011)

Add to Collection

Article Oncology

Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial

Alan K. Burnett et al.

JOURNAL OF CLINICAL ONCOLOGY (2011)

Add to Collection

Article Oncology

Cytarabine Dose of 36 g/m2 Compared With 12 g/m2 Within First Consolidation in Acute Myeloid Leukemia: Results of Patients Enrolled Onto the Prospective Randomized AML96 Study

Markus Schaich et al.

JOURNAL OF CLINICAL ONCOLOGY (2011)

Add to Collection

Letter Oncology

The inv(3)(q21q26)/t(3;3)(q21;q26) is frequently accompanied by alterations of the RUNX1, KRAS and NRAS and NF1 genes and mediates adverse prognosis both in MDS and in AML: a study in 39 cases of MDS or AML

C. Haferlach et al.

LEUKEMIA (2011)

Add to Collection

Article Medicine, General & Internal

Cytarabine Dose for Acute Myeloid Leukemia

Bob Löwenberg et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

Add to Collection

Article Hematology

HLA-Allele Matched Unrelated Donors Compared to HLA-Matched Sibling Donors: Role of Cell Source and Disease Risk Category

Ann Woolfrey et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)

Add to Collection

Review Hematology

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

Hartmut Doehner et al.

BLOOD (2010)

Add to Collection

Article Hematology

Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as AML not otherwise specified (AML-NOS) or AML with myelodysplasia-related changes (AML-MRC)

Miriam Miesner et al.

BLOOD (2010)

Add to Collection

Article Oncology

Clinical, Molecular, and Prognostic Significance of WHO Type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and Various Other 3q Abnormalities in Acute Myeloid Leukemia

Sanne Lugthart et al.

JOURNAL OF CLINICAL ONCOLOGY (2010)

Add to Collection

Article Oncology

Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts

Wah-Seng Lim et al.

LEUKEMIA RESEARCH (2010)

Add to Collection

Review Biophysics

Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia

J. Styczynski et al.

BONE MARROW TRANSPLANTATION (2009)

Add to Collection

Article Hematology

Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation

Nicolaus Kroeger et al.

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)

Add to Collection

Article Hematology

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

ML Sorror et al.

BLOOD (2005)

Add to Collection

Article Oncology

Prognostic index for adult patients with acute myeloid leukemia in first relapse

DA Breems et al.

JOURNAL OF CLINICAL ONCOLOGY (2005)

Add to Collection

© Peeref 2019-2024. All rights reserved.